Screencancer has announced that it has added the Insure FIT take-at-home colorectal cancer screening test to its European cancer screening programme.
The company's two-year distribution agreement with Enterix, a subsidiary of Quest Diagnostics, grants Screencancer exclusive rights to offer Insure FIT in 24 countries of the European Union, including France, Germany and the UK.
Insure FIT features a long-handled blue brush to collect two water-based samples - rather than the solid samples required by other FITs (fecal immunochemical tests) or FOBTs (fecal occult blood tests) - and does not require any change in patient diet or medication.
In one study, patients were 66 per cent more compliant in completing the Insure FIT test compared to a leading guaiac-based FOBT test.
